These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21294474)

  • 41. Breakthrough of the year 2013. Cancer immunotherapy.
    Couzin-Frankel J
    Science; 2013 Dec; 342(6165):1432-3. PubMed ID: 24357284
    [No Abstract]   [Full Text] [Related]  

  • 42. Checkpoint Blockade for the Treatment of Advanced Melanoma.
    Callahan MK; Flaherty CR; Postow MA
    Cancer Treat Res; 2016; 167():231-50. PubMed ID: 26601865
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunotherapy Combo Effective in Melanoma.
    Cancer Discov; 2015 Jul; 5(7):OF1. PubMed ID: 26069187
    [No Abstract]   [Full Text] [Related]  

  • 44. Case of the month. Autoimmune colitis secondary to CTLA-4 blockade.
    Tsiaras A
    JAAPA; 2011 Aug; 24(8):68. PubMed ID: 21850925
    [No Abstract]   [Full Text] [Related]  

  • 45. [Treatment of metastatic melanoma with CTLA4 antibodies].
    Hafner C
    Hautarzt; 2010 Sep; 61(9):808-10. PubMed ID: 20721523
    [No Abstract]   [Full Text] [Related]  

  • 46. QnAs with James Allison.
    Nair P
    Proc Natl Acad Sci U S A; 2016 Aug; 113(33):9131-2. PubMed ID: 27506789
    [No Abstract]   [Full Text] [Related]  

  • 47. Ipilimumab (Yervoy) for metastatic melanoma.
    Med Lett Drugs Ther; 2011 Jun; 53(1367):51-2. PubMed ID: 21701442
    [No Abstract]   [Full Text] [Related]  

  • 48. How should we use anti-CTLA-4 antibodies?
    Marabelle A; Eggermont A
    Eur J Cancer; 2015 Nov; 51(17):2686-8. PubMed ID: 26613660
    [No Abstract]   [Full Text] [Related]  

  • 49. Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?
    Klein O; Kee D; Nagrial A; Markman B; Underhill C; Michael M; Behren A; Palmer J; Tebbutt NC; Carlino MS; Cebon J
    Cancer; 2023 Apr; 129(7):1129-1130. PubMed ID: 36692958
    [No Abstract]   [Full Text] [Related]  

  • 50. What role can LAG-3-blocking antibodies play in melanoma therapy?
    Rutkowski P; Jagodzińska-Mucha P
    Expert Opin Biol Ther; 2023; 23(12):1155-1158. PubMed ID: 37936502
    [No Abstract]   [Full Text] [Related]  

  • 51. Antibody-drug conjugate for advanced melanoma?
    Sharma SP
    Lancet Oncol; 2014 Nov; 15(12):e534. PubMed ID: 25602109
    [No Abstract]   [Full Text] [Related]  

  • 52. International Melanoma Research Congress--Foundation for Melanoma Research. 21-24 June 2003, Philadelphia, PA, USA.
    Swart GW
    IDrugs; 2003 Aug; 6(8):752-4. PubMed ID: 12971393
    [No Abstract]   [Full Text] [Related]  

  • 53. Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy.
    Pol J; Kroemer G
    Cell Res; 2018 May; 28(5):501-502. PubMed ID: 29593340
    [No Abstract]   [Full Text] [Related]  

  • 54. A New Combination Immunotherapy in Advanced Melanoma.
    Frampton AE; Sivakumar S
    N Engl J Med; 2022 Jan; 386(1):91-92. PubMed ID: 34986291
    [No Abstract]   [Full Text] [Related]  

  • 55. Response to the letter: Hyperprogression in advanced melanoma is not restricted to immunotherapy.
    Fournier M; Mortier L; Dereure O; Dalac S; Oriano B; Dalle S; Lebbé C
    Eur J Cancer; 2024 Mar; 200():113562. PubMed ID: 38307775
    [No Abstract]   [Full Text] [Related]  

  • 56. An anti-CTLA-4 heavy chain-only antibody with enhanced T
    Gan X; Shan Q; Li H; Janssens R; Shen Y; He Y; Chen F; van Haperen R; Drabek D; Li J; Zhang Y; Zhao J; Qin B; Jheng MJ; Chen V; Wang J; Rong Y; Grosveld F
    Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2200879119. PubMed ID: 35925889
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies.
    Cheng H; Sun G; Chen H; Li Y; Han Z; Li Y; Zhang P; Yang L; Li Y
    Am J Cancer Res; 2019; 9(8):1536-1545. PubMed ID: 31497341
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent advances and future of immunotherapy for glioblastoma.
    Kamran N; Calinescu A; Candolfi M; Chandran M; Mineharu Y; Asad AS; Koschmann C; Nunez FJ; Lowenstein PR; Castro MG
    Expert Opin Biol Ther; 2016 Oct; 16(10):1245-64. PubMed ID: 27411023
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.
    Tarhini A
    Scientifica (Cairo); 2013; 2013():857519. PubMed ID: 24278787
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Heat shock proteins, autoimmunity, and cancer treatment.
    Calderwood SK; Stevenson MA; Murshid A
    Autoimmune Dis; 2012; 2012():486069. PubMed ID: 23056925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.